A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Ponesimod (VSP-128) in patients with moderately to severely active ulcerative colitis
Male and female subjects aged 18-75 years
Able to provide written informed consent
Diagnosis of ulcerative colitis for ≥90 days prior to screening
Three-component Mayo score of 5-9 with endoscopy subscore ≥2 and rectal bleeding subscore ≥1
Severe or fulminant UC likely to require hospitalization or surgery
Diagnosis of Crohn's disease or other non-UC colitis
Prior exposure to S1P receptor modulators
Active or chronic infections